Skip to content

A Comparative Study of Tumor Specific Mesocolic Excision and Complete Mesocolic Excision for Right Sided Colon Cancer : Asian Multicenter Retrospective Study

A Comparative Study of Tumor Specific Mesocolic Excision and Complete Mesocolic Excision for Right Sided Colon Cancer : Asian Multicenter Retrospective Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06865586
Enrollment
3326
Registered
2025-03-10
Start date
2015-01-01
Completion date
2025-01-15
Last updated
2025-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colon Cancer, Laparoscopic Colon Surgery, Lymph Node Dissection, Robotic Surgical Procedure

Keywords

colon cancer, right hemicolectomy, complete mesocolic excision, lymph node dissection, microinvasive surgery

Brief summary

The goal of this observational study is to determine the optimal surgical strategy based on oncologic outcomes in patients with stage I-III right-sided colon cancer who underwent curative right hemicolectomy. The main question it aims to answer is: Is there a significant difference in 5-year recurrence-free survival (RFS) between patients treated with Complete Mesocolic Excision (CME) and those treated with tumor specific mesocolic excision (TSME)? Participants will include patients who underwent curative right hemicolectomy for right-sided colon cancer between 2015 and 2020 at eight institutions. They will be categorized into two groups based on the surgical technique received-CME group and TSME group-and evaluated for primary and secondary endpoints of 5-year recurrence-free survival (RFS) and overall survival (OS), respectively.

Detailed description

This observational, population-based cohort study was conducted following the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines, with approval obtained from the institutional review board (IRB) of the primary institution and the ethics committees of each participating institution in the Republic of Korea, Hong Kong, and Taiwan. Given that the study utilized anonymized retrospective data, the requirement for informed consent was waived. The study aimed to evaluate the efficacy and safety of Tumor Specific Mesocolic Excision (TSME) compared to Complete Mesocolic Excision (CME) in patients with right-sided colon cancer. Patients diagnosed with right-sided colon cancer who underwent laparoscopic or robotic right hemicolectomy between 2015 and 2020 were included. Surgical techniques were classified into modified TSME or CME, and the study assessed oncologic outcomes, including recurrence-free survival (RFS), overall survival (OS), lymph node yield, and stage distribution. Data collection was conducted at multiple medical centers across Asia to ensure a diverse representation of patient demographics and clinical practices. The participating institutions included Asan Medical Center, Korea University Anam Hospital, Severance Hospital, Kyungpook National University Chilgok Hospital, Chinese University of Hong Kong, North District Hospital, Pamela Youde Nethersole Eastern Hospital, and China Medical University Hospital. These centers, varying in location and size, enhance the study's generalizability within the context of right-sided colon cancer management in Asia.

Interventions

None listed

Sponsors

Korea University Anam Hospital
CollaboratorOTHER
Kyungpook National University Chilgok Hospital
CollaboratorOTHER
Severance Hospital
CollaboratorOTHER
Chinese University of Hong Kong
CollaboratorOTHER
Pamela Youde Nethersole Eastern Hospital
CollaboratorOTHER
North District Hospital
CollaboratorOTHER
China Medical University Hospital
CollaboratorOTHER
Asan Medical Center
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Patients who underwent laparoscopic or robotic right hemicolectomy from 2015 to 2020 * Patients who received curative right hemicolectomy with lymphadenectomy

Exclusion criteria

* Familial adenomatous polyposis (FAP) * Hereditary non-polyposis colon cancer (HNPCC) * Patients with inflammatory bowel disease * Patients with synchronous malignancies in other organs * Patients with non-adenocarcinoma histology of colon cancer * Patients with follow-up duration of less than 3 months

Design outcomes

Primary

MeasureTime frameDescription
5 year Recurrence free survivalOutcome measures will be assessed at 5 years post-surgery.Recurrence-Free Survival (RFS) between patients who underwent TSME and CME procedures from 2015 to 2020

Secondary

MeasureTime frameDescription
Overall survivalOutcome measures will be assessed at 5 years post-surgery.Overall survival (OS) between patients who underwent TSME and CME procedures form 2015 to 2020

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026